Form D · Biotechnology
Neurogastrx, Inc.
Woburn, MA · CIK 0001870700
Offering snapshot reported Jul 13, 2021 · SEC filing
- Reported sold
- $60M Indefinite offering
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 13, 2021 | Initial | $60,000,002 | No comparison | Not reported | SEC filing |
| Jul 6, 2021 | Initial | $20,000,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-406093
Source: Form D, filed Jul 13, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Allison | Director |
| Cyril De Colle | Director, Executive |
| James Detore | Executive |
| Kevin Koch | Director |
| James O'mara | Director, Executive |
| Paul Rogers | Executive |
| Aaron Royston | Director |
| Klaus Veitinger | Director |
| Klaus Vettinger | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
600 Unicorn Park Drive
Woburn, MA, 01801
Woburn, MA, 01801